Price a cancer drug by how well it works in each cancer
A drug that adds a year of life in one cancer and six weeks in another sells at the same price for both; indication-specific prices would pay for the benefit actually delivered.
Overview
Most oncology drugs carry several indications with very different benefit. Indication-based pricing sets a price per indication, either through separate national drug codes or through rebates keyed to the diagnosis on the claim. Italy and Germany use indication-level agreements; in the US, pharmacy benefit managers have run pilots. The barrier is claims data that reliably carries the indication.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
Pages like this
not linked directly; found by shared links- IdeaTie coverage and copays to the ESMO benefit scale
Shares ICER and health technology assessment, European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains.
- IdeaCap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains, Prices and value.
- IdeaGive subcutaneous immunotherapy in community clinics and at home
Shares Atezolizumab, Prices and value, Nivolumab, Pembrolizumab.
- IdeaAutomatic price cuts when a cancer drug's approved indications and volumes expand
Shares Prices and value, Nivolumab, Pembrolizumab.
- IdeaPublicly funded dose-reduction trials of expensive approved drugs
Shares Incentives reward me-too drugs and marginal gains, Prices and value, Nivolumab, Pembrolizumab.
- IdeaLaunch prices indexed to the ESMO benefit scale, revisited when survival matures
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains, Prices and value.
- IdeaPay a different price for the same cancer drug depending on the indication
Shares European Society for Medical Oncology (ESMO), Prices and value, Pembrolizumab.
- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares Atezolizumab, Prices and value, Nivolumab, Pembrolizumab.